Bromantane: what does this study show?
728 patients with psychoautonomic syndrome and asthenic disorders were analyzed across 28 Russian centers. Ladasten 50–100 mg daily for 28 days, with follow-up one month later; route is not specified in the abstract.
Symptoms and quality-of-life scores improved. Adverse effects were reported in 3%, and 0.8% discontinued treatment; no serious adverse effects were reported.
No concurrent control group is described in this abstract. Improvement does not establish a placebo-adjusted effect or benefit for healthy users.
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
No concurrent control group is described in this abstract. Improvement does not establish a placebo-adjusted effect or benefit for healthy users.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.